Introduction
People infected with human immunodeficiency virus (HIV) are at higher risk of coronary heart disease than the general population. 1 This increased risk is explained by a higher prevalence of cardiovascular risk factors, underlying chronic inflammation with immune activation and microbial translocation, and the cardiometabolic effects of antiretroviral drugs (particularly protease inhibitors) favouring dyslipidaemia, insulin resistance, and lipodystrophy. 1 Whether patients infected with HIV develop accelerated atherothrombosis remains a matter of debate. Increased subclinical atherosclerosis, particularly coronary artery disease with increased prevalence of high-risk coronary plaques, has been established in HIV-infected (HIV) patients, 2 while higher prevalence of a prothrombotic state, including higher platelet reactivity, has not. There is evidence for a higher risk of myocardial infarction in the HIV population, particularly after discontinuation of antiretroviral therapy (ART). 3 On the other hand, increased platelet reactivity has been associated in some studies with exposure to ART containing abacavir, a nucleoside reverse transcriptase inhibitor frequently combined with protease inhibitors leading to a controversial increased risk of myocardial infarction. [4] [5] [6] The PACS-HIV study was the first to prospectively demonstrate a higher rate of recurrent ischaemic events and a worse long-term prognosis after a first episode of acute coronary syndrome (ACS) in HIV versus uninfected (non-HIV) patients. 7, 8 This finding was later confirmed in a meta-analysis. 9 However, the underlying mechanisms of this association have not been fully explored. We hypothesized that one potential mechanism for the increased risk of recurrent ACS might be higher on-treatment platelet reactivity in HIV patients, which was shown to be an independent risk factor of major adverse cardiovascular events after percutaneous coronary intervention (PCI) or ACS. 10, 11 To this end, we conducted the EVERE 2 ST-HIV (EValuation of REsidual Platelet Reactivity after acute coronary syndrome, STþ/ST-, in HIV) study to compare platelet reactivity under aspirin and P2Y 12 inhibitor therapy, using validated platelet function tests, between HIV and non-HIV patients with a first episode of ACS on dual antiplatelet therapy (DAPT).
Methods
Study population EVERE 2 ST-HIV was a cross-sectional study conducted in patients with documented ACS and treated with PCI in two cardiac centers (Pitié-Salpêtrière Hospital and Saint-Antoine Hospital) in Paris, France. From December 2012 to August 2014, patients with an ACS were recruited consecutively in the AFIJI (Appraisal ok risk Factors in young Ischaemic Patients Justifying aggressive Intervention) 12 and the ONASSIST (Online ASSIstance for Stent Thrombosis) registries. 13 Acute coronary syndrome patients with and without HIV infection were matched 1:2 based on age (±5 years), sex, smoking status, diabetes mellitus, and various DAPT combinations including aspirin þ clopidogrel, aspirin þ prasugrel, and aspirin þ ticagrelor. The flow chart of the study is presented in Figure 1 .
Patients were recruited during regular follow-up visits in the outpatient clinic or at the Paris-Est Clinical Investigation Centre (CIC-1421). The study inclusion criteria were age >18 years, having experienced an ACS at least 1-month prior to being treated with PCI, and chronic treatment (>30 days) with dual antiplatelet therapy, comprising aspirin 75-320 mg/ day and a thienopyridine (clopidogrel 75 mg/day, prasugrel 10 mg/day, or ticagrelor 90 mg bid). Patients were excluded from the study if they were not covered under the French national healthcare system, if they were taking oral anticoagulant or received glycoprotein IIb/IIIa inhibitors (GPI) within the last 7 days. The Institutional Review Board of Saint-Antoine Hospital (Paris, France) approved the study. All patients gave written informed consent. 
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Data collection
Data on demographic characteristics, medical history, and family history of coronary artery disease were recorded. Past and current medications were recorded as well as drug intake before platelet function testing, to evaluate drug-drug interactions. Data on current ART were obtained for the HIV group, including exposure to nucleoside reverse transcriptase inhibitors (including abacavir separately), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, and integrase inhibitors. Illicit drug use was recorded (defined as use of cannabis, cocaine, or heroin at least once a week).
Blood sampling and measurements
All participants had a fasting blood sample taken to evaluate glycaemia and lipid levels along with creatinine, C-reactive protein and platelet count. In the HIV group, additional immunological and virological variables were measured (CD4þ T-cell count, CD8þ T-cell count, and HIV-1 RNA viral load) using commercially available techniques. For platelet function testing, blood samples were drawn by venipuncture on fasting patients who verbally confirmed taking medication, and the first 2-4 mL of blood was discarded to avoid spontaneous platelet activation. Blood was collected in Becton-Dickinson 3.2% citrate vacuette tubes and samples were processed for platelet function tests within 2 h after blood draw. Technicians were blinded to any patient identifying information.
Light transmission aggregometry
Platelet-rich plasma was obtained by centrifugation of citrated whole blood at 100 g for 10 min at room temperature. Platelet-poor plasma was obtained by further centrifugation at 2250 g for 15 min. In vitro platelet aggregation in platelet-rich plasma was measured at 37 C by light transmission aggregometry (LTA) (model 490-4D, Chrono-Log Corp, Kordia, the Netherlands) and was induced by adding 5 mL of adenosine diphosphate (ADP) (Sigma-Aldrich, Saint Quentin Fallavier, France) at final concentrations of 20 mmol/L for response to P2Y 12 receptor inhibitor testing, and by adding 1.3 mL of arachidonic acid (AA), at a final concentration of 1.25 mmol/L for aspirin testing, with a constant agitation speed of 1200 rpm. Maximal platelet aggregation (MPA) and residual platelet aggregation (RPA) measured 6 min after induction of aggregation by agonist were recorded for both agonists (ADP and AA). Pre-specified criteria used to define non-evaluable samples were lack of sufficient signal, haemolysis, and unstable baseline.
VerifyNow P2Y 12 assay
Platelet-function monitoring was performed using the VerifyNow assay (Accumetrics Corporation, San Diego, CA, USA), a point-of-care platelet-function test that uses two different cartridges for aspirin and P2Y 12 inhibitors. 14 For evaluation of P2Y 12 -mediated platelet reactivity, samples were run locally according to the VerifyNow P2Y 12 package insert at the same time as LTA. Results were expressed in P2Y 12 reaction units (PRU) in response to iso-thrombin receptor activating peptide and in response to ADP-prostaglandin E1. Iso-thrombin receptor activating peptide strongly activates platelets despite P2Y 12 receptor blockage by thienopyridine or aspirin and reflects the platelet reactivity without treatment. 15 The device provides an estimated inhibition (in percentage) without preclopidogrel samples by reporting the ratio of results from the ADPprostaglandin E1 and iso-thrombin receptor activating peptide channels. For aspirin, results were expressed in aspirin reaction units (ARU), and were measured at the same time as LTA.
Vasodilator-stimulated phosphoprotein
Vasodilator-stimulated phosphoprotein (VASP) phosphorylation was measured by Flow Cytometry (FC) using a Beckman Coulter FC500 cytometer (Beckman Coulter, Villepinte, France) according to the manufacturer's instructions, as described. 16 
Genotyping
Genomic DNA was extracted from peripheral blood and was genotyped for the loss of function CYP2C19 variant (*2) using TaqMan validated single nucleotide polymorphism assays (C_25986767_70) with the 7900HT sequence detection system (Applied Biosystems, Courtaboeuf, France). DNA for genotyping was available in 73.3% of the total study population (specific informed consent).
Objectives
The main objective of this study was to evaluate platelet reactivity in response to different P2Y 12 inhibitors (clopidogrel 75 mg, prasugrel 10 mg, or ticagrelor 90 mg bid) and to aspirin. The second objective was to evaluate the proportion of patients with high on-treatment platelet reactivity (HPR), defined by previously established thresholds for each test. 17 HPR for P2Y 12 receptor antagonists was defined by: RPA with 20 mM >46.2% via LTA; MPA with 20 mM >59%; PRU > 208 with the VN-P2Y 12 assay or PRI >50% for the VASP assay and HPR for aspirin was defined by RPA with AA > _20% via LTA or by ARU >550.
Statistical analysis
Based on previous platelet function studies, 14, 16 we evaluated our sample size on the response to clopidogrel and we postulated that the average RPA values in response to ADP in HIV patients would be 16%. Assuming standard deviations of 15% within mean values and a type 1 error of 0.05, 80 ACS patients with HIV and 160 ACS patients without HIV would be needed to achieve 85% power to detect a 1unit difference using Student's t test. For all endpoints, HIV patients and non-HIV patients were compared using the Kruskal-Wallis or Student's t test for continuous variables and the Pearson v 2 or Fisher's exact test for categorical variables. To assess the role of confounding variables on differences between groups, mixed-effect linear regression models were employed in which the correlation observed within matched triads was corrected using a random-intercept. A variable indicating HIV-status, whose parameter estimate allowed calculation of the absolute difference of a given endpoint (D) between HIV and non-HIV patients, was first modelled in univariable analysis. A multivariable model was then constructed by adding the following covariates selected a priori: age, sex, ethnicity/race, body mass index, current smoking status, diabetes, family history of cardiovascular disease, and impaired renal function. Finally, the odds of HPR were compared between HIV and non-HIV patients using a logistic regression model while accounting for within-triad correlation using a cluster sandwich variance estimator. Odds ratios (OR) were then adjusted using the 
Results
Study population
Two-hundred and forty patients were included in the EVERE 2 ST-HIV study: 80 ACS patients infected with HIV and 160 ACS patients without HIV. All patients were taking aspirin. Clopidogrel was the most commonly used P2Y 12 receptor inhibitor taken by 68% of patients overall (HIV, n = 54; non-HIV, n = 108) followed by prasugrel 10 mg in 31% of patients (HIV, n = 25; non-HIV, n = 50) and ticagrelor 90 mg bid in 1% of patients (HIV, n = 1; non-HIV, n = 2). The baseline characteristics of the study population are provided in Table 1 . Patients were predominately male. HIV patients were more likely to have a history of illicit drug use, chronic consumption of alcohol, known dyslipidaemia (hypercholesterolemia and hypertriglyceridemia), and moderate renal failure. In contrast, ACS patients Continuous variables are presented as means and standard deviations and categorical data are presented as absolute frequencies (counts) and percentages. *indicates a P value < 0.05.
without HIV had higher body mass index, LDL cholesterol level, and platelet count than patients with HIV. ST segment elevation myocardial infarction was observed in half of patients; there were no significant differences in the extent of coronary artery disease, the number of percutaneous coronary interventions, or left ventricular ejection fraction according to HIV status, with the exception of a higher percentage of drug-eluting stents in non-HIV patients. There was also no difference in the distribution of CYP2C19*2 loss of function allele (*1/ *2 or *2/*2) between HIV and non-HIV ACS patients (25% vs. 30%, respectively, P = 0.9). HIV-related variables are presented in Table 2 . Patients infected with HIV had on average more than 15 years of known HIV seropositivity and were for the most part virologically suppressed. All HIVþ patients were on ART, most commonly with protease inhibitors [n = 44, including darunavir (68%), lopinavir (16%), atazanavir (11%), and indinavir (5%)]. Nearly all protease inhibitors prescribed were ritonavir-boosted except for 2 patients undergoing atazanavir alone. Thirty-five percent of HIVþ patients were undergoing the nucleoside reverse transcriptase inhibitor abacavir.
P2Y 12 receptor-mediated platelet reactivity
Results of the three platelet function tests used to evaluate platelet reactivity to P2Y 12 inhibitors are presented in Figure 2 . The relative increase of P2Y 12 -mediated platelet aggregation in HIV patients was 55.5% for RPA, 23 .4% for PRU and 40.6% for VASP-PRI. The increase of platelet reactivity among HIV patients was largest in those treated by clopidogrel, however platelet reactivity remained significantly higher in patients treated with third-generation P2Y 12 inhibitors (prasugrel or ticagrelor), as displayed in Table 3 . In multivariable analysis, increased platelet reactivity remained significantly higher in HIV patients after adjustment for known risk factors of HPR and was consistent across the three platelet function tests ( Table 4) .
The prevalence of HPR in response to P2Y 12 inhibitors was significantly higher in HIV than non-HIV patients, respectively, at 25% vs. 8% (P < 0.001) with the RPA, 23% vs. 14% (P = 0.08) with the PRU , and 39% vs. 21% (P = 0.01) with the VASP-PRI. After adjustment, HIV status was still significantly associated with higher prevalence of HPR with adjusted-OR: OR 7.6 [95%CI 3.3-17.3 Table 4) .
Platelet reactivity under aspirin
Acute coronary syndrome patients with HIV had significantly higher RPA (P = 0.004) and higher ARU (P = 0.002) than patients without HIV (Figure 3) . Accordingly, HPR in response to aspirin therapy was significantly more frequent in HIV than non-HIV patients, respectively, when measured with the ARU (14.0% vs. 1 .9%, P = 0.004) or when measured by the RPA (5.2% vs. 0.6%, P = 0.04). After adjustment, HIV status was significantly associated with higher HPR prevalence according to the ARU (OR = 11.5, 95%CI = 1.9-68.7, P = 0.007), but tended to be associated with higher HPR for the RPA (OR = 6.9, 95%CI = 0.7-65.3, P = 0.09).
Impact of HIV-related factors on platelet reactivity
The results of specific HIV-related and ART characteristics among HIV patients and their association with platelet reactivity in response to P2Y 12 inhibitors are displayed in Table S2 ).
Discussion
The results of the EVERE 2 ST-HIV study can be summarized as follows: (1) ACS patients infected with HIV have significantly and consistently higher platelet reactivity on chronic DAPT (either to aspirin or to P2Y 12 inhibitors) as compared with ACS patients without HIV; varying potency, although data were limited with prasugrel and especially for ticagrelor; (3) HIV status is independently associated with an increase in platelet reactivity with all tests and also with higher prevalence of HPR patients to both P2Y 12 inhibitors and to aspirin; and finally (4) exposure to protease inhibitors is associated with increased platelet reactivity. In the EVERE 2 ST-HIV study, we assessed the specific effect of HIV status by matching post ACS patients with and without HIV for major determinants linked to platelet reactivity as a means of overcoming the limitations of previous studies and lowering the potential influence of confounding factors. 14, 18 In addition, the key genetic polymorphism associated with the metabolism of P2Y 12 receptor inhibitors was similarly distributed between infection groups, and its effects consistent in both groups (data not shown). 12 We also used a combination of validated platelet function tests to enhance the consistency of our results. With this in consideration, we were able to demonstrate that ACS patients with HIV exhibit an D's and their 95% confidence intervals (CI) were directly estimated from a mixed-effect linear regression model accounting for the correlation observed within matched triads using a random intercept. Odds ratios (OR) and their 95% CIs were directly estimated from a logistic regression model while accounting for within-triad correlation using a cluster sandwich variance estimator. First, the virus itself is known to affect platelet activity; as internalization of HIV into platelets, resulting in increased platelet activation, has been demonstrated in a murine model and confirmed in human platelets. 19, 20 Human immunodeficiency virus patients exhibit increased spontaneous platelet aggregation and aggregation in response to ADP, collagen, and arachidonic acid as well as increased levels of platelet activation markers (sP-selectin and sCD40L) and microparticles. [21] [22] [23] An increase in markers of platelet activation and aggregation was found in a recent work among HIV individuals naïve of ART and was correlated with higher HIV viral load. 24 Moreover, multiple markers related to inflammation (interleukin-6, tumour necrosis factor, C-reactive protein) and coagulation (tissue factor expression, factor VIII, thrombin, fibrinogen and D-dimer levels) are also increased during HIV infection and have the potential to act on platelet activation and aggregation. Previous researches have also highlighted the link between ART and increased platelet reactivity. In fact, ART can have a significant effect on the activity of purinergic system ectoenzymes at the surface of the platelets leading to increase platelet aggregation 25 and others
showed that platelet aggregation in response to arachidonic acid after a week of aspirin therapy remained elevated in HIV patients treated by ART. 23 Finally, ART could also affect response to antiplatelet therapy through drug-drug interactions modifying hepatic cytochrome drug metabolism, which are known to alter the efficacy of P2Y 12 inhibitors.
We have provided a guide on the interactions between ART and antiplatelet agents adapted from a previous work from Egan et al. (Table  6) . 26 In summary, prasugrel is the recommended P2Y 12 inhibitors for use with protease inhibitors or cobicistat; both of which are potent CYP3A4 inhibitors, can decrease concentrations of the active metabolite of clopidogrel, and are contraindicated for ticagrelor use due to the increased risk of bleeding. Moreover, prasugrel or ticagrelor should be used with the NNRTIs efavirenz and etravirine, which are inhibitors of the CYP2C19 and 2C9 enzymes and are associated with a decrease in the active metabolite of clopidogrel. For other NNRTIs, such as nevirapine and rilpivirine, all integrase inhibitors, and maraviroc, there are no expected interactions with P2Y 12 inhibitors. However, it needs to be stressed that most pharmacological studies are often of limited sample size, are testing a single antiplatelet agent with a single platelet function test, and do not adjust for potential confounding variables associated with platelet reactivity. Therefore, recommendations on the type of DAPT in ACS patients with HIV infection should be done at the individual level after carefully evaluating the risk of drug-drug interactions between all P2Y 12 inhibitors and ART as with statins. 27 When analysing determinants specifically linked to HIV status or associated with ART, we found that protease inhibitor use was independently associated with increased P2Y 12 mediated platelet reactivity. These findings may explain the higher risk of myocardial infarction reported in HIV patients treated with protease inhibitors, 1 although no study to date has extended these results to platelet aggregation or activation. Surprisingly, current exposure to NNRTIs was associated with a significant decrease in P2Y 12 mediated platelet reactivity. These findings are in contrast with previously reported results showing a negative drug-drug interaction between efavirenz (a frequent prescribed NNRTI) and clopidogrel. not support an effect of abacavir on platelet reactivity in HIV patients on DAPT. 5, 6 Some effect was found with the reported use of illicit drugs, which included cocaine use, but was inconsistent within the different platelet function tests used. In particular, the effect of cocaine on platelet aggregation and reactivity is unclear given the contradictory results of several studies. 29, 30 We also found that patients with low CD4 cell counts had an increase in P2Y 12 mediated platelet reactivity which could be associated with increased chronic inflammation, higher viral load altogether leading to increase platelet reactivity. 24 
Limitations
The main limitation of our study is the modest sample size and bias inherent to a cross-sectional study. Our results do not allow us to draw definitive conclusions regarding the effect of ART (direct effect or drug-drug interaction) on high platelet reactivity and would likely need to be validated in a well-designed randomized controlled trial including control groups. Importantly, this study was not designed to evaluate clinical endpoints, and we can only speculate that high platelet reactivity to aspirin and/or P2Y 12 inhibitors, which is an established marker of stent thrombosis and higher mortality in coronary 13, 31 would also translate into an increased risk of these events in the HIV population. A small proportion of HIV subjects was also co-infected with hepatitis B and/or C virus in the present study, both of which may have induced higher platelet reactivity in the HIV group via higher systemic inflammation and impaired liver function. Hepatitis C virus may also account for the lower mean platelet count observed in the HIV group, as it is known to provoke thrombocytopenia. Unfortunately, we were unable to differentiate the specific effects of viral hepatitis in the present work and their impact on platelet reactivity should be evaluated in specific studies. Active metabolites for P2Y 12 receptors inhibitors could not be measured nor could we assess drug compliance in a manner other than selfdeclaration during patient consultation. Finally, as antiretroviral therapy is given without cost in France, our study population was extensively treated with high rates of undetectable viral loads. Our results might not be comparable to other populations, where access to healthcare and treatment is limited.
Conclusion
The EVERE 2 ST findings confirm our hypothesis that ACS patients with HIV versus without HIV exhibit increased levels of platelet reactivity and increased prevalence of HPR when treated with P2Y 12 receptors inhibitors and aspirin. We also found that patients treated with protease inhibitors have an increase in platelet reactivity, which deserve further investigation. All together, these findings may provide an explanation for the poor prognosis of HIV patients treated for an ACS and strongly support the need to conduct outcome studies to determine their clinical relevance and evaluate the most effective combination of antiplatelet and antiretroviral agents, both of which are constantly evolving.
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